Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 50 versus DEXTROSE 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 50 versus DEXTROSE 60.
DEXTROSE 50% vs DEXTROSE 60%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intravenous administration of 50% dextrose solution rapidly elevates blood glucose levels by providing exogenous glucose, which is taken up by cells via glucose transporters and metabolized to produce adenosine triphosphate (ATP), thereby correcting hypoglycemia.
Dextrose is a monosaccharide that provides a source of calories and hydration. It increases blood glucose levels and is metabolized to carbon dioxide and water, yielding energy.
For hypoglycemia: 25 grams (50 mL of 50% solution) intravenous bolus, may repeat once if needed. For insulin-induced hypoglycemia: 25-50 grams intravenously.
Intravenous: For hypoglycemia, 0.5-1 g/kg (10-25 g) as 50% solution; for hyperkalemia, 25 g dextrose with 10 units regular insulin IV. For parenteral nutrition, variable per metabolic needs. Infusion rate not to exceed 0.5 g/kg/h.
None Documented
None Documented
2-4 hours (exogenous glucose); in critically ill patients or hyperglycemic states, half-life may be prolonged due to impaired glucose utilization.
5–10 minutes (for glucose itself; dextrose is glucose). Clinically, rapid distribution and metabolism.
Primarily eliminated by cellular metabolism to carbon dioxide and water; renal excretion of unchanged glucose occurs when plasma concentration exceeds renal threshold (approximately 180 mg/dL), accounting for <5% of elimination under normoglycemic conditions.
Renal: 100% (unchanged) if renal threshold not exceeded; otherwise, glucosuria. Biliary/fecal: negligible.
Category C
Category C
Intravenous Hypertonic Dextrose Solution
Intravenous Hypertonic Dextrose Solution